AB Science SA (ABS.PA) Key Developments | Reuters.com
Edition:
United States

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

13.72EUR
11:35am EDT
Change (% chg)

€0.21 (+1.55%)
Prev Close
€13.51
Open
€13.80
Day's High
€13.90
Day's Low
€13.50
Volume
87,885
Avg. Vol
169,739
52-wk High
€19.90
52-wk Low
€8.62

Latest Key Developments (Source: Significant Developments)

Ab Science announces positive Phase 3 results from Masitinib study
Monday, 30 Nov 2015 12:15pm EST 

AB Science SA:Announces positive top-line results from phase 3 trial of Masitinib in adults with severe systemic mastocytosis.  Full Article

AB Science says unblinding of phase 3 mastocytosis study data planned for November
Tuesday, 6 Oct 2015 12:28pm EDT 

AB Science SA:Unblinding of phase 3 mastocytosis study data planned for Nov. 2015.Based on pooled data taken from two phase 2 studies in mastocytosis, results are indicative of outcome expected for on-going phase 3 study.Announced communication of new phase 2 data in systemic severe mastocytosis aimed at simulating targeted phase 3 study population and response criteria.Near to complete first phase 3 clinical trial ever in mastocytosis.  Full Article

AB Science announces cessation of its rheumatoid arthritis study
Monday, 21 Sep 2015 12:00pm EDT 

AB Science SA:Announces cessation of its rheumatoid arthritis study in order to focus on clinical studies with a probability of success greater than 50 percent.  Full Article

AB Science SA's Masitinib receives Orphan Drug Designation for Stomach Cancer from FDA
Wednesday, 16 Sep 2015 12:08pm EDT 

AB Science SA:Says FDA has granted the company Orphan Drug designation for masitinib in the treatment of esophagogastric adenocarcinoma.Says launched a confirmatory phase 3 trial evaluating masitinib at 6 mg/kg/day in combination with irinotecan in second-line.Says study's primary endpoint is overall survival.  Full Article

AB Science announces successful non futility test for masitinib in progressive forms of multiple sclerosis
Thursday, 23 Jul 2015 01:45pm EDT 

AB Science SA:Announces successful non futility test for masitinib in progressive forms of multiple sclerosis.Independent data safety monitoring committee recommends continuation of phase 3 study based on review of safety and efficacy data.  Full Article

AB Science receives recommendation to continue phase III for masitinib in c-Kit mutated metastatic melanoma
Tuesday, 21 Jul 2015 12:30pm EDT 

AB Science SA:Announces successful futility test for masitinib in c-Kit mutated metastatic melanoma.Independent data safety monitoring committee recommends continuation of phase 3 study.Study plans to enroll 120 patients.  Full Article

AB Science Ab Science initiates new phase of study with masitinib
Wednesday, 15 Jul 2015 12:00pm EDT 

AB Science SA:Announces initiation of an adaptive design phase 2/3 study with masitinib in patients with refractory metastatic ovarian cancer.  Full Article

Ab Science says DSMB recommends continuation of three phase 2 studies
Thursday, 2 Jul 2015 11:58am EDT 

AB Science SA:The Data and Safety Monitoring Board (DSMB)recommends continuation of three phase 2 studies.Studies are assessing masitinib, one in second-line treatment of advanced hepatocellular carcinoma, another in second-line treatment of breast cancer, and the third in second or third-line treatment of head and neck squamous cell carcinoma.  Full Article

Ab Science announces update on masitinib program
Thursday, 25 Jun 2015 01:30am EDT 

AB Science SA:Announces update on phase 1/2 program with masitinib in solid tumors.  Full Article

AB Science Mastinib in peripheral t-cell lymphoma accelerated into phase 3
Wednesday, 27 May 2015 12:48pm EDT 

AB Science SA:Phase 2 with Masitinib in peripheral T-cell lymphoma accelerated into phase 3.  Full Article

BRIEF-AB Science: Rapporteurs appointed by EMA have recommended filing of masitinib in ALS for conditional marketing authorization

* Rapporteurs appointed by EMA have recommended filing of masitinib in amyotrophic lateral sclerosis (ALS) for conditional marketing authorization